The antioxidant effect of erythropoietin on thalassemic blood cells

Anemia

Volumn 2010, Issue , 2010, Pages

  Amer, Johnny ^a   Dana, Mutaz ^a   Fibach, Eitan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

EID: 84873861592     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2010/978710     Document Type: Article

References (85)

1. Krantz S. B., Erythropoietin. Blood 1991 77 3 419 434
2. Jelkmann W., Erythropoietin: structure, control of production, and function. Physiological Reviews 1992 72 2 449 489 2-s2.0-0026526168
3. Lodish H. F., Hilton D. J., Klingmuller U., Watowich S. S., Wu H., The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harbor Symposia on Quantitative Biology 1995 60 93 104 2-s2.0-0029551268 (Pubitemid 26202024)
4. Beutel G., Ganser A., Risks and benefits of erythropoiesis-stimulating agents in cancer management. Seminars in Hematology 2007 44 3 157 165 2-s2.0-34447095903 10.1053/j.seminhematol.2007.04.004 (Pubitemid 47031226)
5. Coladonato J. A., Frankenfield D. L., Reddan D. N., Klassen P. S., Szczech L. A., Johnson C. A., Owen W. F., Trends in anemia management among US hemodialysis patients. Journal of the American Society of Nephrology 2002 13 5 1288 1295 2-s2.0-0036240443 10.1097/01.ASN.0000013294.11876.80 (Pubitemid 34441410)
6. Eschbach J. W., Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness. Journal of the American Society of Nephrology 2002 13 5 1412 1414 2-s2.0-0036232280 10.1097/01.ASN.0000016440. 52271.F7 (Pubitemid 34441425)
7. Kaupke C. J., Kim S., Vaziri N. D., Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. Journal of the American Society of Nephrology 1994 4 11 1874 1878 2-s2.0-0028437998
8. Chaidos A., Makis A., Hatzimichael E., Tsiara S., Gouva M., Tzouvara E., Bourantas K. L., Treatment of β -thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. Acta Haematologica 2004 111 4 189 195 2-s2.0-2642529230 10.1159/000077551 (Pubitemid 38716193)
9. Goldberg M. A., Brugnara C., Dover G. J., Schapira L., Lacroix L., Bunn H. F., Hydroxyurea and erythropoietin therapy in sickle cell anemia. Seminars in Oncology 1992 19 3 74 81 2-s2.0-0026668327
10. Kohli-Kumar M., Marandi H., Keller M. A., Guertin K., Hvizdala E., Use of hydroxyurea and recombinant erythropoietin in management of homozygous β thalassemia. Journal of Pediatric Hematology/Oncology 2002 24 9 777 778 2-s2.0-0036898542 10.1097/00043426-200212000-00021 (Pubitemid 35448749)
11. Rachmilewitz E. A., Aker M., The role of recombinant human erythropoietin in the treatment of thalassemia. Annals of the New York Academy of Sciences 1998 850 129 138 2-s2.0-0031876330 10.1111/j.1749-6632.1998.tb10470.x (Pubitemid 28369754)
12. Dore F., Bonfigli S., Gaviano E., Pardini S., Cianciulli P., Papa G., Longinotti M., Serum erythropoietin levels in thalassemia intermedia. Annals of Hematology 1993 67 4 183 186 2-s2.0-0027491026 (Pubitemid 23295593)
13. Manor D., Fibach E., Goldfarb A., Rachmilewitz E. A., Erythropoietin activity in the serum of beta thalassemic patients. Scandinavian Journal of Haematology 1986 37 3 221 228 2-s2.0-0023019498 (Pubitemid 17183142)
14. Olivieri N. F., Freedman M. H., Perrine S. P., Dover G. J., Sheridan B., Essentine D. L., Nagel R. L., Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. Blood 1992 80 12 3258 3260 2-s2.0-0027096261 (Pubitemid 23004536)
15. Rachmilewitz E. A., Aker M., Perry D., Dover G., Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. The British Journal of Haematology 1995 90 2 341 345 2-s2.0-0029044458
16. Singer S. T., Sweeters N., Vichinsky E. P., A dose-finding and safety study of darbepoietin alfa (erythropoiesis stimulating protein) for the treatment of anemia in patients with thalassemia intermedia. Blood 2003 102 268a
17. Polenakovic M., Sikole A., Is erythropoietin a survival factor for red blood cells? Journal of the American Society of Nephrology 1996 7 8 1178 1182 2-s2.0-0030377624 (Pubitemid 27468270)
18. Lang F., Lang K. S., Lang P. A., Huber S. M., Wieder T., Mechanisms and significance of eryptosis. Antioxidants and Redox Signaling 2006 8 7-8 1183 1192 2-s2.0-33746810505 10.1089/ars.2006.8.1183 (Pubitemid 44182417)
19. Bonomini M., Sirolli V., Settefrati N., Dottori S., Di Liberato L., Arduini A., Increased erythrocyte phosphatidylserine exposure in chronic renal failure. Journal of the American Society of Nephrology 1999 10 9 1982 1990 2-s2.0-0032773209 (Pubitemid 29402520)
20. Myssina S., Huber S. M., Birka C., Lang P. A., Lang K. S., Friedrich B., Risler T., Wieder T., Lang F., Inhibition of erythrocyte cation channels by erythropoietin. Journal of the American Society of Nephrology 2003 14 11 2750 2757 2-s2.0-0142213938 10.1097/01.ASN.0000093253.42641.C1 (Pubitemid 37305637)
21. Lang K. S., Lang P. A., Bauer C., Duranton C., Wieder T., Huber S. M., Lang F., Mechanisms of suicidal erythrocyte death. Cellular Physiology and Biochemistry 2005 15 5 195 202 2-s2.0-20944439110 10.1159/000086406 (Pubitemid 40868969)
22. Amer J., Goldfarb A., Fibach E., Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells. Cytometry Part A 2004 60 1 73 80 2-s2.0-3042779559 (Pubitemid 38859203)
23. Eldor A., Rachmilewitz E. A., The hypercoagulable state in thalassemia. Blood 2002 99 1 36 43 2-s2.0-0036092892 10.1182/blood.V99.1.36 (Pubitemid 34532962)
24. Amer J., Atlas D., Fibach E., N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells. Biochimica et Biophysica Acta 2008 1780 2 249 255 2-s2.0-38549144785 10.1016/j.bbagen.2007.11.009
25. Yang B., Kirby S., Lewis J., Detloff P. J., Maeda N., Smithies O., A mouse model for β -thalassemia. Proceedings of the National Academy of Sciences of the United States of America 1995 92 25 11608 11612 2-s2.0-0029589914 10.1073/pnas.92.25.11608 (Pubitemid 26014162)
26. Fibach E., Measurement of total and fetal hemoglobin in cultured human erythroid cells by a novel micromethod. Hemoglobin 1993 17 1 41 53 2-s2.0-0027463395 (Pubitemid 23053635)
27. Amer J., Fibach E., Oxidative status of platelets in normal and thalassemic blood. Thrombosis and Haemostasis 2004 92 5 1052 1059 2-s2.0-9144245631 10.1160/TH04-04-0234 (Pubitemid 39545529)
28. Amer J., Goldfarb A., Fibach E., Flow cytometric measurement of reactive oxygen species production by normal and thalassaemic red blood cells. European Journal of Haematology 2003 70 2 84 90 2-s2.0-0037331669 10.1034/j.1600-0609. 2003.00011.x (Pubitemid 36269554)
29. Amer J., Ghoti H., Rachmilewitz E., Koren A., Levin C., Fibach E., Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. The British Journal of Haematology 2006 132 1 108 113 2-s2.0-33644792819 10.1111/j.1365-2141.2005.05834.x (Pubitemid 43381577)
30. Lang P. A., Huober J., Bachmann C., Kempe D. S., Sobiesiak M., Akel A., Niemoeller O. M., Dreischer P., Eisele K., Klarl B. A., Gulbins E., Lang F., Wieder T., Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel. Cellular Physiology and Biochemistry 2006 18 1-3 151 154 2-s2.0-33747363968 10.1159/000095190
31. Bratosin D., Mitrofan L., Palii C., Estaquier J., Montreuil J., Novel fluorescence assay using calcein-AM for the determination of human erythrocyte viability and aging. Cytometry Part A 2005 66 1 78 84 2-s2.0-20944442355 10.1002/cyto.a.20152 (Pubitemid 40868922)
32. Pavlova L. E., Savov V. M., Petkov H. G., Charova I. P., Oxidative stress in patients with beta-thalassemia major. Prilozi 2007 28 1 145 154 2-s2.0-38449109114
33. Wood K. C., Granger D. N., Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clinical and Experimental Pharmacology and Physiology 2007 34 9 926 932 2-s2.0-34447513984 10.1111/j.1440-1681.2007.04639.x (Pubitemid 47083959)
34. Chan A. C., Chow C. K., Chiu D., Interaction of antioxidants and their implication in genetic anemia. Proceedings of the Society for Experimental Biology and Medicine 1999 222 3 274 282 2-s2.0-0032726828 (Pubitemid 129708642)
35. Shinar E., Rachmilewitz E. A., Oxidative denaturation of red blood cells in thalassemia. Seminars in Hematology 1990 27 1 70 82 2-s2.0-0025060810 (Pubitemid 20033164)
36. Amer J., Etzion Z., Bookchin R. M., Fibach E., Oxidative status of valinomycin-resistant normal, β -thalassemia and sickle red blood cells. Biochimica et Biophysica Acta 2006 1760 5 793 799 2-s2.0-33646075753 10.1016/j.bbagen.2006.01.012
37. Das Choudhury T., Das N., Chattopadhyay A., Datta A. G., Effect of oxidative stress and erythropoietin on cytoskeletal protein and lipid organization in human erythrocytes. Polish Journal of Pharmacology 1999 51 4 341 350 2-s2.0-0032885056 (Pubitemid 29415649)
38. Balasubramanian K., Bevers E. M., Willems G. M., Schroit A. J., Binding of annexin V to membrane products of lipid peroxidation. Biochemistry 2001 40 30 8672 8676 2-s2.0-0035979351 10.1021/bi010841y (Pubitemid 32709498)
39. Iuliano L., Colavita A. R., Leo R., Praticò D., Violi F., Oxygen free radicals and platelet activation. Free Radical Biology and Medicine 1997 22 6 999 1006 2-s2.0-0031050511 10.1016/S0891-5849(96)00488-1 (Pubitemid 27084137)
40. Mundle S. D., Advances in erythropoietic growth factor therapy for myelodysplastic syndromes. Expert Opinion on Biological Therapy 2006 6 11 1099 1104 2-s2.0-33750812514 10.1517/14712598.6.11.1099 (Pubitemid 44714138)
41. Olivieri N. F., Reactivation of fetal hemoglobin in patients with β -thalassemia. Seminars in Hematology 1996 33 1 24 42 2-s2.0-0030039970 (Pubitemid 26064766)
42. Bourantas K. L., Georgiou I., Seferiadis K., Fetal globin stimulation during a short term trial of erythropoietin in HbS/beta-thalassemia patients. Acta Haematologica 1994 92 2 79 82 2-s2.0-0028590160
43. Breymann C., Fibach E., Visca E., Huettner C., Huch A., Huch R., Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. Journal of Maternal-Fetal and Neonatal Medicine 1999 8 1 1 7 2-s2.0-0032907249 (Pubitemid 29070266)
44. Joyeux-Faure M., Cellular protection by erythropoietin: new therapeutic implications? Journal of Pharmacology and Experimental Therapeutics 2007 323 3 759 762 2-s2.0-36348966705 10.1124/jpet.107.127357 (Pubitemid 350146047)
45. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H. H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Rüther E., Kochen M., Gefeller O., Gleiter C., Wessel T. C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., Sirén A. L., Erythropoietin therapy for acute stroke is both safe and beneficial. Molecular Medicine 2002 8 8 495 505 2-s2.0-0036705708 (Pubitemid 36337492)
46. Zhang F., Wang S., Cao G., Gao Y., Chen J., Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiology of Disease 2007 25 1 45 53 2-s2.0-33751114189 10.1016/j.nbd.2006.08.007 (Pubitemid 44765216)
47. Ofir R., Qing W., Krup M., Weinstein Y., Identification of genes induced by interleukin-3 and erythropoietin via the Jak-Stat5 pathway using enhanced differential display-reverse southern. Journal of Interferon and Cytokine Research 1997 17 5 279 286 2-s2.0-0031006758 (Pubitemid 27244090)
48. Morishita E., Masuda S., Nagao M., Yasuda Y., Sasaki R., Erythropoetin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1996 76 1 105 116 2-s2.0-0030636320 10.1016/S0306-4522(96)00306-5 (Pubitemid 26407940)
49. Erbayraktar S., Yilmaz O., Gokmen N., Brines M., Erythropoietin is a multifunctional tissue-protective cytokine. Current Hematology Reports 2003 2 6 465 470
50. Fiordaliso F., Chimenti S., Staszewsky L., Bai A., Carlo E., Cuccovillo I., Doni M., Mengozzi M., Tonelli R., Ghezzi P., Coleman T., Brines M., Cerami A., Latini R., A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America 2005 102 6 2046 2051 2-s2.0-13844320400 10.1073/pnas.0409329102 (Pubitemid 40262009)
51. Leis M., Gliezzi P., Grasso G., Bianchi R., Vilia P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Kirstine Larsen A., Helboe L., Christensen S., Pedersen L. O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q. W., Coleman T., Cerami A., acerami@kswi.org Brines M., Derivatives of erythropoitein that are tissue protective but not erythropoietic. Science 2004 305 5681 239 242 10.1126/science.1098313 (Pubitemid 38886736)
52. Moon C., Krawczyk M., Paik D., Coleman T., Brines M., Juhaszova M., Sollott S. J., Lakatta E. G., Talan M. I., Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. Journal of Pharmacology and Experimental Therapeutics 2006 316 3 999 1005 2-s2.0-33644775862 10.1124/jpet.105.094854 (Pubitemid 43345271)
53. Brines M., mbrines@kswi.org Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.-W., Smart J., Su-Rick C.-J., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., Cerami A., Erythropoietin mediates tissue protection through an erythropoietin and common β -subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America 2004 101 41 14907 14912 10.1073/pnas.0406491101 (Pubitemid 39410773)
54. Katavetin P., Inagi R., Miyata T., Shao J., Sassa R., Adler S., Eto N., Kato H., Fujita T., Nangaku M., Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochemical and Biophysical Research Communications 2007 359 4 928 934 2-s2.0-34250630084 10.1016/j.bbrc.2007.05.207 (Pubitemid 46946906)
55. Liu J., Narasimhan P., Yu F., Chan P. H., Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. Stroke 2005 36 6 1264 1269 2-s2.0-20444430402 10.1161/01.STR.0000166180.91042.02 (Pubitemid 40798749)
56. Wang Z. Y., Shen L. J., Tu L., Hu D. N., Liu G. Y., Zhou Z. L., Lin Y., Chen L. H., Qu J., Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radical Biology and Medicine 2009 46 8 1032 1041 2-s2.0-63049096543 10.1016/j.freeradbiomed.2008.11.027
57. Li G., Ma R., Huang C., Tang Q., Fu Q., Liu H., Hu B., Xiang J., Protective effect of erythropoietin on β -amyloid-induced PC12 cell death through antioxidant mechanisms. Neuroscience Letters 2008 442 2 143 147 2-s2.0-48149102116 10.1016/j.neulet.2008.07.007
58. Wu Y., Shang Y., Sun S. G., Liu R. G., Yang W. Q., Protective effect of erythropoietin against 1-methyl-4-phenylpyridinium- induced neurodegenaration in PC12 cells. Neuroscience Bulletin 2007 23 3 156 164 2-s2.0-34547124308 10.1007/s12264-007-0023-0 (Pubitemid 47104870)
59. Biswas T., Ghosal J., Ganguly C., Datta A. G., Effect of erythropoietin on the interchange of cholesterol and phospholipid between erythrocyte membrane and plasma. Biochemical Medicine and Metabolic Biology 1986 35 2 120 124 2-s2.0-0022621805 (Pubitemid 16096973)
60. Boran M., Küçükaksu C., Balk M., Çetin S., Red cell lipid peroxidation and antioxidant system in haemodialysed patients: influence of recombinant human erythropoietin (r-HuEPO) treatment. International Urology and Nephrology 1998 30 4 507 512 2-s2.0-0031762464 (Pubitemid 28505795)
61. Cavdar C., Camsari T., Semin I., Gönenc S., Acikgöz O., Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scandinavian Journal of Urology and Nephrology 1997 31 4 371 375 2-s2.0-0030877796 (Pubitemid 27364463)
62. Delmas-Beauvieux M. C., Combe C., Peuchant E., Carbonneau M., Dubourg L., De Precigout V., Aparicio M., Clerc H., Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron. Nephron 1995 69 4 404 410 2-s2.0-0028958504
63. Rud'ko I. A., Balashova T. S., Pokrovsky A., Ermolenko V. M., Kubatiev A. A., The effects of recombinant human erythropoietin on lipid peroxidation and red cell antioxidant resistance in hemodialysis chronics with renal failure. Gematologiya i Transfuziologiya 1993 38 3 24 26 (Pubitemid 23245343)
64. Sommerburg O., Grune T., Hampl H., Riedel E., Van Kuijk F. J. M. G., Ehrich J. H. H., Siems W. G., Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrology Dialysis Transplantation 1998 13 10 2583 2587 2-s2.0-0031692179 10.1093/ndt/13.10.2583 (Pubitemid 28445874)
65. Turi S., Nemeth I., Varga I., Bodrogi T., Matkovics B., The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure. Pediatric Nephrology 1992 6 6 536 541 2-s2.0-0027048686 10.1007/BF00866497 (Pubitemid 23003412)
66. Bany-Mohammed P. M., Slivka S., Hallman M., Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits. Pediatric Research 1996 40 3 381 387 2-s2.0-9444291812 (Pubitemid 26282569)
67. Chakraborty M., Ghosal J., Biswas T., Datta A. G., Effect of erythropoietin on the different ATPases and acetylcholinesterase of rat RBC membrane. Biochemical Medicine and Metabolic Biology 1986 36 2 231 238 2-s2.0-0022455491 (Pubitemid 16008495)
68. Chakraborty M., Ghosal J., Biswas T., Datta A. G., Effect of erythropoietin on membrane lipid peroxidation, superoxide dismutase, catalase, and glutathione peroxidase of rat RBC. Biochemical Medicine and Metabolic Biology 1988 40 1 8 18 2-s2.0-0023710280
69. Chattopadhyay A., Das Choudhury T., Bandyopadhyay D., Datta A. G., Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochemical Pharmacology 2000 59 4 419 425 2-s2.0-0033961724 10.1016/S0006-2952(99)00277-4 (Pubitemid 30015971)
70. Chattopadhyay A., Choudhury T. D., Basu M. K., Datta A. G., Effect of Cu2+ -ascorbic acid on lipid peroxidation, Mg2+ -ATPase activity and spectrin of RBC membrane and reversal by erythropoietin. Molecular and Cellular Biochemistry 1992 118 1 23 30 2-s2.0-0027093587 10.1007/BF00249691 (Pubitemid 23010146)
71. Ghosal J., Biswas T., Ghosh A., Datta A. G., Effect of erythropoietin on the lipid composition of red blood cell membrane. Biochemical Medicine 1984 32 1 1 14 2-s2.0-0021252392 (Pubitemid 14096038)
72. Ghosal J., Chakraborty M., Biswas T., Ganguly C. K., Datta A. G., Effect of erythropoietin on the glucose transport of rat erythrocytes and bone marrow cells. Biochemical Medicine and Metabolic Biology 1987 38 2 134 141 2-s2.0-0023428306
73. Broudy V. C., Lin N., Brice M., Nakamoto B., Papayannopoulou T., Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991 77 12 2583 2590 2-s2.0-0025908919
74. Sawada K., Krantz S. B., Dai C. H., Koury S. T., Horn S. T., Gluck A. D., Civin C. I., Purification of human blood burst-forming units-erythoid and demonstration of the evolution of erythropoietin receptors. Journal of Cellular Physiology 1990 142 2 219 230 2-s2.0-0025159230
75. Baciu I., Ivanof L., Erythropoietin interaction with the mature red cell membrane. Annals of the New York Academy of Sciences 1983 414 66 72 2-s2.0-0020973813 (Pubitemid 14180787)
76. Pedranzini L., Dechow T., Berishaj M., Comenzo R., Zhou P., Azare J., Bornmann W., Bromberg J., Pyridone 6, a Pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Research 2006 66 19 9714 9721 2-s2.0-33750298971 10.1158/0008-5472.CAN-05-4280 (Pubitemid 44623672)
77. Lai P. H., Everett R., Wang F. F., Arakawa T., Goldwasser E., Structural characterization of human erythropoietin. The Journal of Biological Chemistry 1986 261 7 3116 3121 2-s2.0-0022973324 (Pubitemid 17204919)
78. Rowley D. A., Halliwell B., Superoxide-dependent and ascorbate-dependent formation of hydroxyl radicals in the presence of copper salts: a physiologically significant reaction? Archives of Biochemistry and Biophysics 1983 225 1 279 284 2-s2.0-0020636216 (Pubitemid 13044858)
79. Inoue N., Takeuchi M., Asano K., Shimizu R., Takasaki S., Kobata A., Structures of mucin-type sugar chains on human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. Archives of Biochemistry and Biophysics 1993 301 2 375 378 2-s2.0-0027254599 10.1006/abbi.1993.1158 (Pubitemid 23214133)
80. Ogasawara Y., Namai T., Yoshino F., Lee M. C. I., Ishii K., Sialic acid is an essential moiety of mucin as a hydroxyl radical scavenger. FEBS Letters 2007 581 13 2473 2477 2-s2.0-34248549673 10.1016/j.febslet.2007.04.062 (Pubitemid 46764708)
81. Oetke C., Hinderlich S., Brossmer R., Reutter W., Pawlita M., Keppler O. T., Evidence for efficient uptake and incorporation of sialic acid by eukaryotic cells. European Journal of Biochemistry 2001 268 16 4553 4561 2-s2.0-0034825538 10.1046/j.1432-1327.2001.02379.x (Pubitemid 32862866)
82. Calatroni A., Barberi I., Salpietro C., Altered sialic acid contents of red blood cell membrane preparations in homozygous beta-thalassemia. Italian Journal of Biochemistry 1978 27 2 94 103 2-s2.0-0018140481 (Pubitemid 8385308)
83. Kahane I., Ben Chetrit E., Shifter A., Rachmilewitz E. A., The erythrocyte membranes in β -thalassemia. Lower sialic acid levels in glycophorin. Biochimica et Biophysica Acta 1980 596 1 10 17 2-s2.0-0018834539 (Pubitemid 10180377)
84. Bulai T., Bratosin D., Artenie V., Montreuil J., Uptake of sialic acid by human erythrocyte. Characterization of a transport system. Biochimie 2003 85 1-2 241 244 2-s2.0-0038532623 10.1016/S0300-9084(03)00059-2 (Pubitemid 36625998)
85. Yousef G. M., Ordon M. H., Foussias G., Diamandis E. P., Molecular characterization, tissue expression, and mapping of a novel siglec-like gene (SLG2) with three splice variants. Biochemical and Biophysical Research Communications 2001 284 4 900 910 2-s2.0-0034804381 10.1006/bbrc.2001.5053 (Pubitemid 32924732)